Deutsche Bank AG acquired a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) duri

Algert Global LLC purchased a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) du

Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) shares reached a new 52-week high during

BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“

Rapport Therapeutics is differentiated by RAP-219's neuroanatomically selective pharmacology and a 2

BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains

HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a

BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(1.19) per share which missed the a

RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling

Shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) have been given an average rat

BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains

COO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on

Leerink Partners analyst Marc Goodman initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) wi

Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the

BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“R

Truist Securities analyst Danielle Brill assumes Rapport Therapeutics (NASDAQ:RAPP) with a Buy ra

BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains

Rapport Therapeutics, Inc. (RAPP) came out with a quarterly loss of $0.42 per share versus the Zacks

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.42) per share which beat the ana

Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seiz

MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 La société AdVini annonce avoir mis

MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Dijon, France le 30 avril 2026 (17h45 CET) -- CR

This Boston-based biotech innovator in CNS disorders just reported significant insider selling amid

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90%

A Paris, le 8 avril 2026 COMMUNIQUE INFORMATION REGLEMENTEE Communiqué précisant les modalités de mi

Shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) have been given an average rec

LONDON--(BUSINESS WIRE)--Neuphonic and Rapport (a division of Speech Graphics) today announced a par

BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (

BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the

Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweig

Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may from time to time issue, in one or mor

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.72) per share which missed the a

Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner,

Wells Fargo analyst Benjamin Burnett initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) wit

CLINICAL AND PIPELINE UPDATESRapport is prioritizing programs it believes have the greatest potentia

HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median re

BTIG analyst Kambiz Yazdi initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rat

Citizens analyst Jason N. Butler maintains Rapport Therapeutics (NASDAQ:RAPP) with a Market Outpe

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.71) per share which beat the ana

Truist Securities analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with

Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-st